All canine diagnoses

Your dog was diagnosed with Cardiac Hemangiosarcoma (Right Atrial). Second most common site for HSA after spleen. Right atrium/auricular appendage is typical location. Often presents with pericardial effusion and cardiac tamponade. May occur concurrently with splenic HSA. Compare 5 treatment options for dogs including Pericardiectomy + Auriculectomy + Adjuvant Chemotherapy, Pericardiectomy ± Tumour Debulking (No Chemotherapy), Pericardiocentesis + Palliative Care — with survival times, costs, and what to expect during treatment.

🐕

Cardiac Hemangiosarcoma (Right Atrial)

BreedsGolden RetrieverGerman Shepherd DogLabrador RetrieverMalteseMiniature Dachshund
canine

Mesenchymal

About This Cancer

Cardiac hemangiosarcoma develops in the heart, most commonly in the right atrial appendage, where it arises from the same blood-vessel-lining cells as splenic hemangiosarcoma. The tumour often causes fluid to accumulate in the sac surrounding the heart (pericardial effusion), which can compress the heart and impair its ability to pump — a life-threatening condition called cardiac tamponade. This emergency frequently prompts the initial diagnosis. Cardiac hemangiosarcoma may occur as an isolated tumour or may be found alongside splenic hemangiosarcoma. Surgical access to the heart is more challenging than to the spleen, and complete tumour removal is often difficult, making the overall prognosis more guarded. Golden Retrievers, German Shepherd Dogs, and Labrador Retrievers are most commonly affected.

No standardised staging system exists for primary cardiac HSA. Prognosis is primarily influenced by resectability, metastatic status (concurrent splenic or other site involvement), and treatment approach.

Prognostic Factors(4)
Concurrent splenic HSADual-site disease carries worse prognosis than cardiac HSA alone.
Treatment approachCombined surgery + chemotherapy: MST 189 days vs medical management alone: 27 days.(Yamamoto et al., 2013)
Tumour sizeLarger right atrial masses correlate with worse prognosis and higher risk of intraoperative haemorrhage.
Arrhythmia burdenDogs with haemodynamically significant arrhythmias at presentation may have poorer outcomes and higher surgical risk.
Minimum Workup(6 steps)
1Complete blood count and biochemistry
2Echocardiography (mass identification, effusion assessment)
3Three-view thoracic radiographs
4Abdominal ultrasound (concurrent splenic HSA screening)
5Pericardiocentesis (diagnostic and therapeutic)
6ECG (arrhythmia assessment)

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Pericardiectomy + Auriculectomy + Adjuvant Chemotherapy
~6 mo (4–7)
Pericardiectomy ± Tumour Debulking (No Chemotherapy)
~3 mo (0.5–4)
Pericardiocentesis + Palliative Care
~0.5 mo (0.25–1)
Palliative Radiation Therapy
See notes
Pericardiectomy + Auriculectomy + Adjuvant Carboplatin
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.